TY - JOUR T1 - Platelet and endothelial activation are requisites for the development of antiphospholipid syndrome JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis SP - 600 LP - 601 DO - 10.1136/ard.2003.010694 VL - 63 IS - 5 AU - E del Río García AU - C Rodríguez AU - J Rodríguez-Martorell AU - A Serrano AU - J A Girón-González Y1 - 2004/05/01 UR - http://ard.bmj.com/content/63/5/600.abstract N2 - The antiphospholipid syndrome (APS) is characterised by venous and arterial thrombosis, recurrent fetal loss, and by the presence of antiphospholipid antibodies (aPL).1 aPL are also present in 2% of the healthy population,2,3 and, with the exception of those with high titres of aPL, there is no clear evidence of an increased incidence of thrombosis throughout the follow up.2–4 Thus, one of the key questions is: What causes the development of thrombosis in patients with APS? We suggest that in APS, a persistent procoagulant state,5,6 a continuous endothelial and platelet activation is present, and this may be detected by raised levels of soluble adhesion molecules. We prospectively studied the following groups of subjects: (a) 20 patients … ER -